Introduction {#sec1-1}
============

Diabetes mellitus (DM) is associated with hyperglycemia and is due to abnormal carbohydrate metabolism, which relates to relative or absolute impairment in insulin secretion or utilization in the body.\[[@ref1]\] Diabetic nephropathy (DN) is a kidney disease or damage of kidney, the exact cause of which is indefinite. However, it is assumed that abandoned elevated blood sugar and elevated blood pressure cause damage to the kidney.\[[@ref2]\] DN associated with morphological and ultrastructural changes within the kidney is determined by the clinical manifestation of the disease.\[[@ref3][@ref4]\]

To prevent diabetic complications, a number of plant extracts have been used as a single agent or else formulations because the safety profile of herbal formulations is better than that of oral hypoglycemic agents.\[[@ref5]\] Polyherbal formulation (PHF) is preferred to individual formulation. Still, several herbal formulations such as Cogent db, Hyponidd, Trasina, tincture of punchparna, Diasulin, and Diamed are recommended for diabetes, hyperlipidemia, and oxidative stress.\[[@ref6]\] *Eugenia jambolana*, *Tinospora cordifolia*, *Gymnema sylvestre*, *Cressa cretica*, *Casearia esculenta*, *Curcuma longa*, *Swertia chirata*, *Centratherum anthelminticum*, *Picrorrhiza kurroa*, *Trigonella foenum-graecum*, *Terminalia chebula*, *Holarrhena antidysenterica*, *Pterocarpus marsupium*, *Glycyrrhiza glabra*, Mineral pitch, *Tribulus terrestris*, *Withania somnifera*, *Nardostachys jatamansi*, and *Bacopa monniera* have proven antidiabetic, antihyperlipidemic, and antioxidant activities individually \[[Table 1](#T1){ref-type="table"}\].\[[@ref7][@ref8][@ref9]\] However, no reports are available regarding their effects synergistically in DN. On the basis of the obtained information, the current investigation has been conducted to assess the outcome of PHF on streptozotocin (STZ)-induced DN in rats.

###### 

Phytochemicals present in the plants of polyherbal formulation and their pharmacological properties

  Plant                           Phytochemicals                                                                                                                         Pharmacological properties
  ------------------------------- -------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------
  *Eugenia jambolona*             Jambosine, gallic acid, ellagic acid, corilagin, 3,6-hexahydroxydiphenoylglucose, quercetin, β-sitosterol                              AntidiabeticHypolipidemic
  *Tinospora cordifolia*          Berberine, choline, palmatine, magnoflorine, tinosporine, tetrahydropalmatine, isocolumbine, aporphine alkaloids, tinosporides         AntidiabeticAnti-inflammatory
  *Gymnema sylvestre*             Gymnemic acids, gymnemasaponins, flavones, hentriacontane, pentatriacontane                                                            AntidiabeticHypolipidemic anti-inflammatory
  *Cressa cretica*                Quercetin, kampferol-3-O-glucoside, rutin, syringaresinol-β-d-glucoside                                                                Antidiabetic activity
  *Casearia esculenta*            Clerodane diterpenoids, esculentin A, 3-hydroxymethyl xylitol                                                                          HypoglycemicAnti-inflammatory
  *Curcuma longa*                 Curcumin, desmethoxy curcumin, α and β turmerome, eugenon, campestrol, stigmasterol                                                    AntidiabeticAntihyperlipidemic antioxidant
  *Swertia chirata*               Swertiamarin, mangiferin, swerchirin, sweroside, amaroswerin, amarogentin, chiratin                                                    AntidiabeticAntioxidant
  *Centratherum anthelminticum*   Hexatetracontan-16-ol, 6,9-eicosadiene, butyl 11-hydroxy octadecanoate, hexyl 3-hydroxynonanoate                                       AntidiabeticAntioxidantAnti-inflammatory
  *Picrorhiza kurroa*             Picroside-I and II, pikuroside, veronicoside, phenol glycosides, a number of cucurbitacin glycosides                                   AntidiabeticAntihyperlipidemic
  *Trigonella foenum-graecum*     Diosgenin, amino acid 4-hydroxyisoleucine, yamogenin, tigogenin                                                                        AntidiabeticAntioxidant
  *Terminalia chebula*            Gallic acid, chebulagic acid, punicalagin, chebulanin, corilagin, neochebulinic acid, ellagic acid                                     Antidiabetic antioxidant renoprotective, anti-inflammatory
  *Holarrhena antidysenterica*    Holarrifine, kurchamide, kurcholessine, trimethylconkurchine, N-methylholarrhimine                                                     Antidiabetic antioxidant, anti-inflammatory
  *Pterocarpus marsupium*         Pterostilbene, 7-hydroxyflavanone, isoliquiritigenin, liquiritigenin, dihydroxyflavone, marsupsin, pterosupin, p-hydroxybenzaldehyde   Antihyperinsulinemic, anti-hyper triglyceridaemic
  *Glycyrrhiza glabra*            2-beta-glycyrrhizic, glucuronic acid, glycyrrhetinic acid (enoxolone), tannic acid, asparagine, resins                                 Antidiabetic, antihyperlipidemic anti-inflammatory
  *Mineral pitch*                 Benzoic acid, hippuric acid, fatty acid, gums, resins, ellagic acid, triterpenes                                                       AntidiabeticAntioxidantAnti-inflammatory
  *Tribulus terrestris*           Kaempferol, kaempferol3rutinoside, tribuloside, rutin                                                                                  AntidiabeticHypolipidemicAnti-inflammatory
  *Withania somnifera*            Isopellertierine, anferine, withanolides, withaferins, withanolides                                                                    AntihyperglycemicHypolipidemic antioxidant antiinflammatory
  *Nardostachys jatamansi*        Sesquiterpenes, coumarins, jatamansone or valeranone, alpha-patcho-ulense                                                              Antidiabetic antioxidant
  *Bacopa monnieri*               Brahmine, nicotine, herpestine, D-mannitol, hersaponin                                                                                 Antidiabetic antioxidant

Materials and Methods {#sec1-2}
=====================

Collection of medicinal plants {#sec2-1}
------------------------------

Based on literature, plants which have been reported to possess antidiabetic, antihyperlipidemic, anti-inflammatory, and antioxidant activities are selected. The locally available plants were freshly collected and the remaining herbs were purchased from an Ayurvedic shop in Anantapur and were valid by Professor J. Raveendra Reddy, Division of Pharmacognosy, of our institute.

Polyherbal formulation preparation {#sec2-2}
----------------------------------

The plant materials after air drying were powdered individually in a pulverizer and passed through sieve number 80. Finely powdered 19 herbal ingredients were mixed in the ratio of 8:4 2:2:1, of which eight parts were from single herb, four parts were from two herbs, two parts were from eight herbs, and one part was from the remaining eight herbs (w/w) to obtain a homogenous mixture (order of mixing is mentioned in [Table 2](#T2){ref-type="table"}).\[[@ref10]\]

###### 

Composition of polyherbal formulation

  Botanical name                  Family           Part used   Weight (g)
  ------------------------------- ---------------- ----------- ------------
  *Eugenia jambolana*             Myrtaceae        Seeds       20
  *Tinospora cordifolia*          Menispermaceae   Roots       10
  *Gymnema sylvestre*             Asclepiadaceae   Leaves      10
  *Cressa cretica*                Convolvulaceae   Leaves      5
  *Casearia esculenta*            Hippocrataceae   Roots       5
  *Curcuma longa*                 Zingiberaceae    Rhizome     5
  *Swertia chirata*               Gentianaceae     Leaves      5
  *Centratherum anthelminticum*   Compositae       Seeds       5
  *Picrorhiza kurroa*             Plantaginaceae   Rhizomes    5
  *Trigonella foenum-graecum*     Fabaceae         Seeds       5
  *Terminalia chebula*            Combretaceae     Fruits      5
  *Holarrhena antidysenterica*    Apocynaceae      Bark        2.5
  *Pterocarpus marsupium*         Fabaceae         Leaves      2.5
  *Glycyrrhiza glabra*            Fabaceae         Rhizomes    2.5
  Mineral pitch                   \-               \-          2.5
  *Tribulus terrestris*           Zygophyllaceae   Seeds       2.5
  *Withania somnifera*            Solanaceae       Leaves      2.5
  *Nardostachys jatamansi*        Valirenaceae     Rhizomes    2.5
  *Bacopa monnieri*               Plantaginaceae   Leaves      2.5

Experimental animals {#sec2-3}
--------------------

The male and female Wistar rats (180--200 g) were procured from Raghavendra Enterprises, Bengaluru, Karnataka, India. The animals were maintained at standard conditions and protocol permitted by the Institutional Animal Ethics Committee (Protocol No: 878/AC/05/CPCSEA/024/2011).

Acute toxicity study {#sec2-4}
--------------------

Female rats were separated into four groups, with three animals in each. Overnight fasted animals from Groups 1--4 received PHF (5, 50, 300, and 2000 mg/kg) orally. During 14 days observational period, no abnormal behavior and death were noticed. Hence, two dose levels were chosen, in which the first dose was one-eighth of the upper dose and the other was twice that of the one-eighth dose (250 and 500 mg/kg) selected for *in vivo* studies (Organisation for Economic Co-operation and Development guidelines 423).

Administration of polyherbal formulation to rats {#sec2-5}
------------------------------------------------

First, we took polyherbal churna into a clean motor and grinded it with a pastel and after that, we made the suspension with tween 80. Uniform suspension of churna was given by an oral feeding tube, at the dose of 250 and 500 mg/kg daily between 9.00 am and 10.00 am in order to avoid circadian rhythm.

Induction of diabetes and experimental design {#sec2-6}
---------------------------------------------

STZ was prepared in citrate buffer on the day of induction and injected intraperitoneally to all the groups except normal control (NC). After 48 h, rats with high glucose (≥250 mg/dl) were segregated into four groups (six/group) and were administered the below-mentioned treatment orally for 16 weeks:

NC was administered with normal salineDN control (DNC) animals were adminstered with vehicle onlyDN rats were administered with PHF 250 mg/kgDN rats were administered with PHF 500 mg/kg.

On the last day, serum was separated from blood and stored at 2°C--8°C in a refrigerator until further usage.

Estimation of serum lipid profile {#sec2-7}
---------------------------------

After completion of the treatment schedule, triglyceride (TG) (GPO-PAP method), total cholesterol (TC) (CHOD-PAP method), and high-density lipoprotein (HDL) (precipitating method) were estimated in the collected serum, according to instructions given by commercially available Erba biochemical kits using Erba semi-autoanalyzer (Chem 7, Erba Mannheim, Brentford, London, United Kingdom). Very low-density lipoprotein (VLDL) and LDL were calculated by the Friedewald formula.

Estimation of renal function parameters in serum and urine {#sec2-8}
----------------------------------------------------------

Creatinine (Jaffe method) levels were estimated in serum by using Erba Chem-7 commercially available kit. Individual rats of all groups were kept separately in a metabolic cage for 24 h, and the collected urine samples were measured with a measuring cylinder and the urine volume (ml/24 h) was recorded. The collected urine samples were utilized for the estimation of urinary proteins (biuret method), urea (urease L-glutamate dehydrogenase method), and creatinine (Jaffe method) by using Erba Chem-7 commercially available kits. Type IV collagen in urine samples was estimated by assay protocol given by Abcam enzyme-linked immunosorbent assay (ELISA) kits (Cambridge, MA, USA) (ab 6586). Twenty-four hour urinary albumin excretion rate (UAER) was determined by an earlier available formula.\[[@ref11][@ref12]\]

Estimation of inflammatory cytokines {#sec2-9}
------------------------------------

Inflammatory cytokines in serum: interleukin-6 (IL-6) (ab 100772), transforming growth factor (TGF)-β1 (ab 46780), and tumor necrosis factor-alpha (TNF-α) (ab 9755) levels were estimated according to the procedure by ELISA kits from Abcam (Cambridge, MA, USA).\[[@ref13]\]

Determination of advanced glycation end products in kidney homogenate {#sec2-10}
---------------------------------------------------------------------

Advanced glycation end product (AGES) levels in kidney tissue were estimated according to a method described earlier. In brief, homogenized kidney tissue was imbibed overnight with mixture of chloroform and methanol (2:1 v/v). Following decantation, the remaining residue was mixed with 0.1 N NaOH, and the supernatant was collected after centrifugation (5000 rpm/15 min/4°C). Alkali-solubilized AGES were estimated by quantifying the fluorescence of samples in a fluorescence spectrophotometer at 440 nm (emission wavelength) and 370 nm (excitation wavelength) against blank samples of 1 ml of 0.1 N NaOH. One unit of fluorescence is equivalent to 1 mg/ml of bovine serum albumin (as standard). The fluorescence values of sample protein concentration of 1 mg/ml were measured as arbitrary units.\[[@ref14]\]

Histopathology of kidney {#sec2-11}
------------------------

The kidney tissue was stored in fixing solution (10% buffered formalin) for histopathological examination.

Statistical analysis {#sec2-12}
--------------------

The collected data were evaluated by one-way ANOVA along with Dunnett\'s multiple comparisons test and noted as mean ± standard error of mean.

Results {#sec1-3}
=======

Polyherbal formulation on serum lipid profiles {#sec2-13}
----------------------------------------------

Hyperlipidemia was observed in STZ-DN rats with increase in TG, TC, LDL, and VLDL (*P* \< 0.01) and reduction in HDL (*P* \< 0.01). PHF dose dependently (250 and 500 mg/kg) corrected the hyperlipidemia with decrease in serum TG, TC, VLDL, and LDL (*P* \< 0.01) and rise in HDL (*P* \< 0.05, *P* \< 0.01) in correlation with DN rats \[[Table 3](#T3){ref-type="table"}\].

###### 

Effect of polyherbal formulation on lipid profile

  Group         TGs (mg/dl)       TC (mg/dl)        HDL (mg/dl)       VLDL (mg/dl)       LDL (mg/dl)
  ------------- ----------------- ----------------- ----------------- ------------------ ------------------
  NC            69.4±0.647        87.0±3.06         28.6±1.23         13.8±0.118         38.5±1.92
  DNC           175±1.21\*\*      196.0±6.64\*\*    18.4±0.30\*\*     34.8±0.393\*\*     143±4.37\*\*
  DN + test 1   132±1.16^\#\#^    87.3±2.42^\#\#^   21.2±0.55^\#^     26.3±0.443^\#\#^   92.46±1.20^\#\#^
  DN + test 2   88.1±1.74^\#\#^   79.0±1.46^\#\#^   24.0±0.78^\#\#^   17.4±0.280^\#\#^   61.7±2.50^\#\#^

\*\**P*\<0.01 compared with NC, ^\#\#^*P*\<0.01 compared with DNC, ^\#^*P*\<0.05 compared with DNC. All values are expressed as mean±SEM. DN rats treated with dose (250 mg/kg/orally) of formulation (DN + test 1), dose (500 mg/kg/orally) of formulation (DN + test 2), respectively. TGs=Triglycerides, TC=Total cholesterol, DN=Diabetic nephropathy, NC=Normal control, DNC=DN control, SEM=Standard error of mean, HDL=High-density lipoprotein, LDL=Low-density lipoprotein, VLDL=Very LDL

Polyherbal formulation on renal function tests {#sec2-14}
----------------------------------------------

STZ-DN rats displayed a significant decrease in 24-h urine volume, urinary urea, and urine creatinine (*P* \< 0.01) and increase in serum creatinine, protein in urine, UAER, AGES, and type IV collagen excretion (*P* \< 0.01). PHF at 250 and 500 mg/kg body weight (bw) doses demonstrated a significant increase in 24-h urine volume, urine creatinine (*P* \< 0.01), and urinary urea (*P* \< 0.05 and *P* \< 0.01) and a significant decrease in protein in urine, UAER, AGES, and type IV collagen excretion (*P* \< 0.01) in correlation with DN rats \[Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}\].

###### 

Effect of polyherbal formulation on renal function tests

  Group         Urine volume (ml/rat/day)   Urinary urea (mg/dl)   Serum creatinine (mg/dl)   Urine creatinine (mg/dl)
  ------------- --------------------------- ---------------------- -------------------------- --------------------------
  NC            11.3±0.80                   5.33±0.98              0.6±0.03                   26.6±1.45
  DNC           4.0±0.26\*\*                0.01±0.01\*\*          2.40±0.42\*\*              5.8±0.99\*\*
  DN + test 1   17.8±1.70^\#\#^             2.67±1.090^\#^         1.12±0.02^\#\#^            20.1±1.16^\#\#^
  DN + test 2   13.2±1.05^\#\#^             3.67±0.33^\#\#^        0.943±0.02^\#\#^           23.8±0.70^\#\#^

\*\**P*\<0.01 compared with NC, ^\#\#^*P*\<0.01 compared with DNC, ^\#^*P*\<0.05 compared with DNC. All values are expressed as mean±SEM. DN rats treated with dose (250 mg/kg/orally) of formulation (DN + test 1), dose (500 mg/kg/orally) of formulation (DN + test 2), respectively. DN=Diabetic nephropathy, NC=Normal control, DNC=DN control, SEM=Standard error of mean

###### 

Effect of polyherbal formulation on renal function tests

  Group         Protein in urine (mg/day)   UAER (µg/day)    AGES (AU)        Type IV collagen excretion (µg/day)
  ------------- --------------------------- ---------------- ---------------- -------------------------------------
  NC            0.23±0.042                  1.8±0.33         197±14.3         16.3±3.48
  DNC           24.70±0.422\*\*             16.8±1.51\*\*    455±57.7\*\*     750±76.4\*\*
  DN + test 1   0.56±0.098^\#\#^            6.0±0.57^\#\#^   252±19.2^\#\#^   80.0±5.77^\#\#^
  DN + test 2   0.08±0.030^\#\#^            2.9±0.56^\#\#^   227±22.0^\#\#^   68.3±5.63^\#\#^

\*\**P*\<0.01 compared with NC, ^\#\#^*P*\<0.01 compared with DNC. ll values are expressed as mean±SEM. DN rats treated with dose (250 mg/kg/orally) of formulation (DN + test 1), dose (500 mg/kg/orally) of formulation (DN + test 2), respectively. DN=Diabetic nephropathy, NC=Normal control, DNC=DN control, SEM=Standard error of mean, UAER=Urinary albumin excretion rate, AGES=Advanced glycation end products, AU=Arbitrary unit

Polyherbal formulation on inflammatory mediators {#sec2-15}
------------------------------------------------

STZ-DN rats displayed a considerable rise in IL-6, TGF-β1, and TNF-α (*P* \< 0.01). DN rats with PHF at 250 and 500 mg/kg bw doses demonstrated a significant decrease in IL-6, TGF-β, and TNF-α (*P* \< 0.01) in correlation with DN rats \[[Table 6](#T6){ref-type="table"}\].

###### 

Effect of polyherbal formulation on inflammatory mediators

  Group         IL-6 (Pg/ml)     TGF-β1 (%)        TNF-α (Pg/ml)
  ------------- ---------------- ----------------- -----------------
  NC            164±4.80         12.7±2.19         34.2±4.55
  DNC           361±11.6\*\*     25.5±2.57\*\*     368±37.1\*\*
  DN + test 1   275±5.62^\#\#^   13.2±1.74^\#\#^   140±10.6^\#\#^
  DN + test 2   252±8.72^\#\#^   13.3±1.33^\#\#^   75.0±7.64^\#\#^

\*\**P*\<0.01 compared with NC, ^\#\#^*P*\<0.01 compared with DNC. All values are expressed as mean±SEM. DN rats treated with dose (250 mg/kg/orally) of formulation (DN + test 1), dose (500 mg/kg/orally) of formulation (DN + test 2), respectively. DN=Diabetic nephropathy, NC=Normal control, DNC=DN control, SEM=Standard error of mean, IL=Interleukin, TGF-β=Transforming growth factor-beta, TNF-α=Tumor necrosis factor-alpha

Histopathology of kidney {#sec2-16}
------------------------

Kidney tissues revealed histopathological alteration as follows: (a) normal rats -- normal histological architecture; (b and c) DNC rats -- accumulation of inflammatory cells, hypotropic glomeruli, and hemorrhagic spots; (d) PHF (250 mg/kg bw) -- normal glomerular architecture; (e) PHF (500 mg/kg bw): normal architecture of the tubules and glomeruli \[[Figure 1](#F1){ref-type="fig"}\].

![Histopathology of rat\'s kidney (a) Normal rats, (b and c) DNC rats, (d) PHF (250mg/kg b.w), (e) PHF (500mg/kg b.w)](IJPharm-51-330-g001){#F1}

Discussion {#sec1-4}
==========

DN is the most common complication of DM which results in end-stage renal failure and is observed in 30%--40% of diabetic patients. Among the sufferers of DN, about 50% need either dialysis or kidney replacement, which not only affects their quality of life but also imposes financial burden. Currently available antidiabetic drugs have fewer efficacies toward the prevention and progression of DN and even drugs acting on renin--angiotensin--aldosterone system pathway are clinically approved, but still fail to get considerable results. Although understanding of molecular mechanism underlying DN is not clear, considerable literatures mentioned the importance of hyperglycemia-induced AGES as one of the key factors which further initiates the sequential chain activation of oxidative stress, inflammation, and fibrosis in DN.\[[@ref15]\] The pathological complexity of the above motivated many researchers to inculcate the multitargeted therapeutic approach rather than single approach. Moreover, the same thing was practiced in the clinical settings of the alternative system of medicine, such as Ayurveda, Siddha, and Unani in India since ancient times.\[[@ref16]\] Hence, we tried to explore the renoprotective effect of an in-house polyherbal churna formulated with herbs which has been proved to possess antidiabetic, antioxidant, anti-inflammatory, and antifibrotic activities.\[[@ref17]\] From the literature, it is very clear that lipid/lipoprotein abnormalities are a commonly observed status in type-II DM that are risk factors for renal atherosclerosis formation and further affect the renal blood flow.\[[@ref18]\] Pretreatment of DN rats with PHF at doses 250 and 500 mg/kg bw remarkably decreased the TG, TC, VLDL, and LDL and improved the HDL levels dose dependently, and it was clearly witnessed from the existence of known medicinal herbs with antihyperlipidemic active principles of polyherbal churna (*Gymnema sylvestre* -- gymnemic acids, gymnemasaponins). STZ-challenged rats exhibited the characteristic features of DN such as increased amount of serum creatinine, proteins in urine, UAER as well as decrease in urinary urea, urine volume, and urine creatinine, which are the outcomes of hyperglycemia-activated multipathological signaling pathways in DN.\[[@ref19]\] PHF pretreatment (250 and 500 mg/kg) corrected the imbalance of pathological characteristics in a dose-dependent manner. Accumulated evidence clear that sustained hyperglycemia enhances the formation of AGES. Interaction of AGES with its RAGE receptor in kidney activated various signaling pathways related to inflammation, fibrosis, and oxidative stress.\[[@ref20]\] An increased amount of AGES in kidney tissue was observed in DN rats. Amelioration of AGES levels in kidney tissue by PHF at doses of 250 and 500 mg/kg bw is the best evidence for the nephroprotective mechanism of PHF (*Tribulus terrestris* -- tribuloside, *Eugenia jambolana* -- jambosine).\[[@ref21][@ref22]\] Type IV collagen is an important component of the extracellular matrix of mesangial and glomerular basement membrane. Excessive deposition of type IV collagen in the extracellular matrix is due to hyperglycemia-induced synthesis and also due to decreased breakdown by the glycation of protein component of collagen, which causes renal fibrosis and excretion of type IV collagen in the urine which is an early hallmark of renal fibrosis.\[[@ref23]\] STZ induced DN rats observed with significant increase in urinary excretion of type IV collagen and is efficiently decreased with PHF at doses 250, 500 mg/kg and this suggests that anti-fibrotic mechanism of PHF (*Glycyrrhiza glabra* -- glycyrrhetinic acid, *Curcuma longa* -- curcumin).\[[@ref24]\] Accumulation of pro-inflammatory cytokines (IL-6, TNF-α, and TGF-β1) is a well-established event in the progression of DN; to be very specific, TNF-α enhances the production of free radicals and causes apoptosis and necrosis of renal tissue. STZ-induced DN rats showed increased levels of IL-6, TNF-α, and TGF-β1 and treatment with PHF at 250 and 500 mg/kg bw showed reduction of IL-6, TNF-α, and TGF-β1, suggesting the presence of anti-inflammatory constituents (*Curcuma longa* -- curcumin, *Tribulus terrestris* -- tribuloside, and rutin).\[[@ref21][@ref22]\] Histopathological changes are the most evident indicator of renal damage, and DN causes noticeable glomeruli, tubular damages, and hemorrhagic conditions. PHF efficiently protects the internal structure of kidney. At the end, our results expressed that PHF exhibited better nephroprotective activity by blocking the sequential interaction of oxidative stress, inflammatory pathways, and fibrosis pathways associated with chronic diabetes. Protective effect may be possible due to the presence of known and proven multiple and divergent phytoconstituents of PHF. Hence, PHF can be considered as a therapeutic option in DN. Still, deeper human investigation is necessary to authenticate the useful effects of PHF in DN.

Conclusion {#sec1-5}
==========

At the end, our results expressed that PHF exhibited better nephroprotective activity by blocking the sequential interaction of oxidative stress, inflammatory pathways, and fibrosis pathways associated with chronic diabetes. Protective effect may be possible due to the presence of known and proven multiple and divergent phytoconstituents of PHF. Hence, PHF can be considered as a therapeutic option in DN. Still, deeper human investigation is necessary to authenticate the useful effects of PHF in DN.
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